BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 12907009)

  • 1. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
    Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
    Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
    Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Tham YL; Kalidas M; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; Lewis MT; Wong H; O'Connell P
    J Clin Oncol; 2005 Feb; 23(6):1169-77. PubMed ID: 15718313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of docetaxel response in human breast cancer by gene expression profiling.
    Iwao-Koizumi K; Matoba R; Ueno N; Kim SJ; Ando A; Miyoshi Y; Maeda E; Noguchi S; Kato K
    J Clin Oncol; 2005 Jan; 23(3):422-31. PubMed ID: 15659489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
    Chang JC; Makris A; Gutierrez MC; Hilsenbeck SG; Hackett JR; Jeong J; Liu ML; Baker J; Clark-Langone K; Baehner FL; Sexton K; Mohsin S; Gray T; Alvarez L; Chamness GC; Osborne CK; Shak S
    Breast Cancer Res Treat; 2008 Mar; 108(2):233-40. PubMed ID: 17468949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
    Cleator S; Tsimelzon A; Ashworth A; Dowsett M; Dexter T; Powles T; Hilsenbeck S; Wong H; Osborne CK; O'Connell P; Chang JC
    Breast Cancer Res Treat; 2006 Feb; 95(3):229-33. PubMed ID: 16322899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
    Yoo GH; Piechocki MP; Ensley JF; Nguyen T; Oliver J; Meng H; Kewson D; Shibuya TY; Lonardo F; Tainsky MA
    Clin Cancer Res; 2002 Dec; 8(12):3910-21. PubMed ID: 12473607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
    Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
    Gianni L; Zambetti M; Clark K; Baker J; Cronin M; Wu J; Mariani G; Rodriguez J; Carcangiu M; Watson D; Valagussa P; Rouzier R; Symmans WF; Ross JS; Hortobagyi GN; Pusztai L; Shak S
    J Clin Oncol; 2005 Oct; 23(29):7265-77. PubMed ID: 16145055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
    Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
    Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
    Heys SD; Hutcheon AW; Sarkar TK; Ogston KN; Miller ID; Payne S; Smith I; Walker LG; Eremin O;
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S69-74. PubMed ID: 12435290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
    Ooe A; Kato K; Noguchi S
    Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
    Gogas H; Fountzilas G
    Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
    Korde LA; Lusa L; McShane L; Lebowitz PF; Lukes L; Camphausen K; Parker JS; Swain SM; Hunter K; Zujewski JA
    Breast Cancer Res Treat; 2010 Feb; 119(3):685-99. PubMed ID: 20012355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
    Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
    Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
    Barros Filho MC; Katayama ML; Brentani H; Abreu AP; Barbosa EM; Oliveira CT; Góes JC; Brentani MM; Folgueira MA
    Braz J Med Biol Res; 2010 Dec; 43(12):1225-31. PubMed ID: 21103787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant docetaxel in locally advanced breast cancer.
    Hutcheon AW; Heys SD; Sarkar TK;
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S19-24. PubMed ID: 12868802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.